In conjunction with White's appointment, the company announced a reduction in the monthly compensation for Karina Fedasz, the former Interim CEO, and Andrew Oakley, the Lead Independent Director, effective March 18, 2026. This decision reflects the company's commitment to aligning executive compensation with performance and operational efficiency.
Additionally, the company reported the resignation of Timothy Ramdeen from the Board, effective March 19, 2026. Ramdeen's departure was not due to any disagreements with management or the Board, indicating a smooth transition in leadership. Following this, Sammy Dorf was appointed to the Board and the Audit Committee, bringing his entrepreneurial and investment experience to the team. Dorf's background includes significant roles in public companies and expertise in capital formation and governance.
These leadership changes come at a critical time for Onconetix as it seeks to enhance its operational execution and strategic outlook. The appointment of a seasoned executive like White is expected to provide the necessary guidance to navigate the company's future challenges and opportunities. The Board's restructuring, including the addition of Dorf, further strengthens the governance framework, ensuring that the company is well-positioned for growth in the competitive landscape of the biotechnology sector.
